4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Shareholders Equity (Quarterly) : 407.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 407.66M |
| March 31, 2026 | 451.84M |
| December 31, 2025 | 505.66M |
| September 30, 2025 | 368.98M |
| June 30, 2025 | 420.89M |
| March 31, 2025 | 469.72M |
| December 31, 2024 | 510.61M |
| September 30, 2024 | 552.95M |
| June 30, 2024 | 588.34M |
| March 31, 2024 | 600.56M |
| December 31, 2023 | |
| September 30, 2023 | 329.93M |
| June 30, 2023 | 325.14M |
| March 31, 2023 | 218.61M |
| Date | Value |
|---|---|
| December 31, 2022 | 231.34M |
| September 30, 2022 | 251.44M |
| June 30, 2022 | 272.52M |
| March 31, 2022 | 296.06M |
| December 31, 2021 | 319.11M |
| September 30, 2021 | 224.13M |
| June 30, 2021 | 240.65M |
| March 31, 2021 | 242.43M |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 30.01M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 492.62M |
| Total Liabilities (Quarterly) | 84.96M |
| Debt to Equity Ratio | 0.0962 |
| Current Ratio | 8.033 |
| Net Debt Paydown Yield | -0.42% |